ArticleScientific reports2024
Deep learning pipeline for accelerating virtual screening in drug discovery.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "First, do no harm" in the digital era: examining the practicality of the European Health Data Space proposal and ethical implications of artificial intelligence: A systematic literature review.BMC medical ethics · 2026Pooled it
- µORScreen: a lightweight consensus modeling framework for µ-opioid receptor ligand prediction and virtual screening.RSC advances · 2026Article
- An interpretable framework applying protein words to predict protein-small molecule complementary pairing rules.Chemical science · 2026Article
- Article
- HTS-Oracle X: AI-Guided Prospective Discovery of Small Molecule Immune Checkpoint Binders.ACS medicinal chemistry letters · 2026Article
- AI-driven computational drug design: tools, workflow and challenges.RSC advances · 2026Review
- Geometric Deep Learning-Based Drug Design Models for Small-Molecule Drug Discovery.Molecular informatics · 2026Review
- Revolutionizing drug discovery from natural products: The roles of artificial intelligence and multi-omics in accelerating innovation.Acta pharmaceutica Sinica. B · 2026Article
- Screening of Natural Product-Derived USP7 Inhibitors for Cancer Therapy via Integrated Machine Learning and Molecular Simulations.Current issues in molecular biology · 2026Article
- Comprehensive Insights into Natural Bioactive Compounds: From Chemical Diversity and Mechanisms to Biotechnological Innovations and Applications.ChemistryOpen · 2026Review
- 7-Prenyloxycoumarins as Promising Antileishmanial Agents: In Vitro, In Vivo, and In Silico Evaluation AgainstPharmaceuticals (Basel, Switzerland) · 2026Article
- Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect.Journal of computer-aided molecular design · 2026Review
- Integrated Computer-Aided Drug Design: Advances in GPCR Natural Ligand Discovery.Cell biochemistry and biophysics · 2026Review
- TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.Briefings in bioinformatics · 2026Article
- Article
- Recent Advances and Emerging Directions in Machine Learning-Based Breast Cancer Drug Discovery: A Comprehensive Review.Breast cancer (Dove Medical Press) · 2026Review
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
- Artificial intelligence-driven drug discovery: a deep learning paradigm shift in pharmaceutical research and development.Frontiers in pharmacology · 2026Review
- Next-generation osteoarthritis models: integrating biological, computational, and engineering approaches.Stem cell research & therapy · 2025Review
- Host-Microbe Interactions: Prospects of Machine Learning and Deep Learning Technologies in Animal Viral Disease Management.Veterinary sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the race to combat ever-evolving diseases, the drug discovery process often faces the hurdles of high-cost and time-consuming procedures. To tackle these challenges and enhance the efficiency of identifying new therapeutic agents, we introduce VirtuDockDL, which is a streamlined Python-based web platform utilizing deep learning for drug discovery. This pipeline employs a Graph Neural Network to analyze and predict the effectiveness of various compounds as potential drug candidates. During the validation phase, VirtuDockDL was instrumental in identifying non-covalent inhibitors against the VP35 protein of the Marburg virus, a critical target given the virus's high fatality rate and limited treatment options. Further, in benchmarking, VirtuDockDL achieved 99% accuracy, an F1 score of 0.992, and an AUC of 0.99 on the HER2 dataset, surpassing DeepChem (89% accuracy) and AutoDock Vina (82% accuracy). Compared to RosettaVS, MzDOCK, and PyRMD, VirtuDockDL outperformed them by combining both ligand- and structure-based screening with deep learning. While RosettaVS excels in accurate docking but lacks high-throughput screening, and PyRMD focuses on ligand-based methods without AI integration, VirtuDockDL offers superior predictive accuracy and full automation for large-scale datasets, making it ideal for comprehensive drug discovery workflows. These results underscore the tool's capability to identify high-affinity inhibitors accurately across various targets, including the HER2 protein for cancer therapy, TEM-1 beta-lactamase for bacterial infections, and the CYP51 enzyme for fungal infections like Candidiasis. To sum up, VirtuDockDL combines user-friendly interface design with powerful computational capabilities to facilitate rapid, cost-effective drug discovery and development. The integration of AI in drug discovery could potentially transform the landscape of pharmaceutical research, providing faster responses to global health challenges. The VirtuDockDL is available at https://github.com/FatimaNoor74/VirtuDockDL .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.